AmbioPharm - A Global Peptide CDMO

AmbioPharm - A Global Peptide CDMO

Slogan: Global Peptide Contract Development & Manufacturing Organization (CDMO).

Description: AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.

Industries: Biotechnology, Manufacturing

Last Investment: Private Equity Round investment at 10 September 2018

Last Investment Investors: The Carlyle Group

AmbioPharm, founded in 2005, has positioned itself as a formidable player in the global peptide CDMO space. With facilities in the US and China, the company boasts efficient manufacturing processes for peptide-based APIs, catering to clients worldwide. The recent Private Equity Round investment on September 10, 2018, led by The Carlyle Group, underscores investor confidence in the company's growth trajectory. As AmbioPharm continues to expand its footprint and enhance its manufacturing capabilities, it presents an intriguing opportunity for venture capital seeking exposure to the biotechnology and manufacturing sectors.